American International Group, Inc. Inozyme Pharma, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.14 - $7.66 $836 - $1,547	-202 Reduced 0.85%	23,528 $180,000
Q4 2023 Feb 13, 2024	BUY	$2.71 - $4.5 $18,530 - $30,771	6,838 Added 40.48%	23,730 $101,000
Q3 2023 Nov 13, 2023	BUY	$4.09 - $7.0 $2,454 - $4,200	600 Added 3.68%	16,892 $70,000
Q2 2023 Aug 04, 2023	BUY	$4.93 - $6.74 $80,319 - $109,808	16,292 New	16,292 $90,000
Q2 2022 Aug 12, 2022	SELL	$3.2 - $5.96 $22,860 - $42,578	-7,144 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.87 - $7.55 $1,946 - $3,797	-503 Reduced 6.58%	7,144 $29,000
Q4 2021 Feb 11, 2022	SELL	$5.58 - $11.5 $1,272 - $2,622	-228 Reduced 2.9%	7,647 $52,000
Q3 2021 Nov 12, 2021	SELL	$11.12 - $19.4 $2,079 - $3,627	-187 Reduced 2.32%	7,875 $91,000
Q2 2021 Aug 13, 2021	BUY	$15.19 - $21.2 $15,964 - $22,281	1,051 Added 14.99%	8,062 $137,000
Q1 2021 May 07, 2021	BUY	$17.77 - $27.9 $40,639 - $63,807	2,287 Added 48.41%	7,011 $139,000
Q4 2020 Feb 12, 2021	SELL	$19.95 - $27.55 $2,713 - $3,746	-136 Reduced 2.8%	4,724 $98,000
Q3 2020 Nov 04, 2020	BUY	$17.54 - $30.2 $85,244 - $146,772	4,860 New	4,860 $128,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $121M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.